AbbVie Shares Moving Higher On Guidance Announcement

AbbVie  ABBV shares are moving higher in Monday’s pre-market session after the company raised guidance.

Full year guidance is now expected between $3.06 and $3.16 versus $3.00 to $3.10 announced at the end of January. This is a two percent increase from the midpoint. The company also announced that the guidance does not include any potential earnings from the U.S. launch of its hepatitis C therapy that is under accelerated review by the FDA.

Shares of AbbVie were last trading at $54.49, up 2.23 percent since Friday’s close.